Bioptic took part in the AI in Biopharma panel at the 4BIO Capital 2025 AGM & Annual Conference, hosted at the Royal Institution of London. The session brought together leaders from industry and academia to discuss what AI can (and cannot) do for biopharma today — and how practical, narrow AI products are already improving workflows
At the Royal Institution of London, Optic took part in the AI in Biopharma panel during 4BIO Capital’s 2025 AGM & Annual Conference.
Representing Optic, our CEO Andrey Doronichev outlined where AI will (and won’t) create tangible value for the industry in the next few years.
“Most value in the near future will be created not by a ‘magical general AI’ that solves all science at once, but by practical, narrow products that automate pharma workflows and connect dots across science, business, and regulation.”
Key takeaways
- Pragmatism over promises: Focus on deployable tools that measurably cut cycle time and cost.
- Workflow automation first: Data prep, evidence synthesis, due-diligence, and regulatory support are ripe for impact now.
- Cross-functional glue: Value emerges when AI connects scientific signals with business constraints and compliance realities.
- From pilots to scale: Success depends on internal champions, clear KPIs, and evidence over hype.
Thank you to 4BIO Capital for convening an exceptional group of scientists, investors, and pharma leaders to move the field forward.